 to injections. Some analysts expect the weight loss drug market currently dominated by Novo Nordisk's Wagovi and Eli Lilly's Zepbound to be more worth more than $150 billion in annual sales by the early 2030s. The drug maker did not lay out an exact timeline for development of the drug. It plans to evaluate multiple doses of the reformulated drug in the second half of this year and